Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Friday's double-digit pop celebrated a quarter in which three of four brands shrank or stalled. The one that didn't is ...

Target fell out of favor with consumers, but it has started to get back on track, and investors have taken notice.

D-Wave is moving from experiments to live enterprise workloads, but the valuation leaves little room for error. See what ...

Micron is looking beyond today's AI boom. Its latest investments reveal where it sees future demand emerging, but one major ...

Spousal benefits max out at 50% of the amount your spouse is entitled to at full retirement age. If you delay a spousal ...

You learn a lot writing about the stock market, and I've been doing that for a long time. As a contributor to The Motley Fool ...

Momentum stocks, put simply, are stocks that have gone up the most in a given period. The S&P Momentum indexes use the ...

Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

The global shortage of AI chips and components is giving Nvidia an unprecedented ability to dictate prices, which is also a ...

In the earliest stages of the AI boom, this growth resulted in stock price gains, with the shares climbing 800% over the past ...

Then there's Starship. If you're new to SpaceX, here's what you need to know.